Cryoport Launches its IntegriCell™ Cryopreservation Solution with Opening of New Facility at its Houston Campus
Rhea-AI Summary
Cryoport, Inc. (NASDAQ: CYRX) has launched its IntegriCell™ cryopreservation services solution with the opening of a new facility at its Houston campus. The state-of-the-art facility is dedicated to the standardized cryopreservation of leukapheresis material, integrating with Cryoport's end-to-end global temperature-controlled supply chain platform to support cell-based therapies.
The IntegriCell platform aims to enhance cell therapy manufacturing efficiency and flexibility, ensuring safety, quality, and product stability. The Houston site also supports GMP-compliant biostorage and a full suite of bioservices, including secondary packaging, labeling, kit production, and logistics capabilities.
Cryoport's CEO, Jerrell Shelton, stated that the new facility expands their presence in Houston and is a significant milestone in providing integrated supply chain solutions for cell and gene therapies. The company believes IntegriCell will offer the industry's first complete solution for optimized cellular starting materials, potentially accelerating treatment delivery and opening new revenue streams.
Positive
- Launch of IntegriCell™ cryopreservation services solution
- Opening of new state-of-the-art facility in Houston
- Potential for new revenue streams from new and existing customers
- Integration with Cryoport's end-to-end global temperature-controlled supply chain platform
- Expansion of services including GMP-compliant biostorage and bioservices
Negative
- None.
News Market Reaction
On the day this news was published, CYRX declined 0.13%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The IntegriCell Platform Will Deliver High-Quality Cryopreservation Services for Cell-Based Therapies
IntegriCell is a standardized bioprocessing, cryopreservation, and distribution solution for the global cell therapy market. The platform is designed to enhance cell therapy manufacturing efficiency and flexibility, ensuring safety, quality and product stability to support the production of these lifesaving treatments. The Cryoport Systems'
"Our new facility expands our presence on our
The Cryoport Global Supply Chain Center campus in
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Our corporate headquarters, located in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the IntegriCell platform to support the development and commercialization of cell and gene therapies, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-launches-its-integricell-cryopreservation-solution-with-opening-of-new-facility-at-its-houston-campus-302268614.html
SOURCE Cryoport, Inc.
FAQ
What is Cryoport's IntegriCell™ cryopreservation solution?
Where is Cryoport's new IntegriCell™ facility located?
When is the Grand Opening event for Cryoport's new Houston facility?
What services does Cryoport's Houston campus offer?
